Preliminary study shows GLP-1 receptor agonists alter alcohol response, suggesting potential for reducing cravings and ...

This 3-part series looks at the current evidence for the treatment of SUD, alcohol use disorder, and tobacco use disorder.

Researchers are exploring drugs like Ozempic, Mounjaro, and Wegovy to treat or prevent a range of conditions, including ...

Novo Nordisk NVO continues to derive the bulk of its revenue from its blockbuster semaglutide (GLP-1 RA) therapies, Wegovy ...

Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient ...

Rani Therapeutics stock surged 200% after securing a $1 billion partnership with Chugai and raising $60 million in funding.

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

As GLP-1 weight-loss drugs like Ozempic reshape how consumers eat, food and beverage manufacturers are racing to develop ...

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is increasing in clinical trials to treat overlapping ...

The percentage of patients with a GLP-1 RA prescription before metabolic and bariatric surgery increased from 5.6% to 26.9% from 2020 to 2024.

The uptake of GLP-1 drugs is extraordinary. Everyone is either taking them, considering taking them, or knows someone else who has. And it’s this speed of adoption that’s powered the global market to ...